The Catalan biotech enterprise Iproteos, promoted by IRB Barcelona and the University of Barcelona, will apply new strategies to discover drugs with greater efficiency and fewer side effects.
Scientists at Memorial Sloan-Kettering Cancer Center in New York and at IRB Barcelona reveal the mechanism of action of a protein that is essential for life and is associated with disease.
Scientists at IRB Barcelona and the BSC discover that some proteins have chemical bonds that prevent the formation of toxic aggregates.
The study sheds light on how proteins have evolved to prevent the cell toxicity associated with toxic aggregates.
More than 60 particpants took part in the "Career Progression in Science - Options Beyond the Bench" day, held on June 9 in the Auditorium of the Barcelona Science Park (PCB). The event, organized jointly by the Institute for Research in Biomedicine (IRB Barcelona) and the PCB, aimed to create a platform where experts with a background in science, but who have gone on to take up a wide range of careers beyond the bench, could share their personal experiences and provide perspective on alternative careers for students and young researchers.
This year's panelists included: Sarah Sherwood, Head of the Department of Communications and External Relations at IRB Barcelona; Susana...
Using state-of-the-art technology, they seek to unraveled the genome of patients with chronic lymphocytic leukemia and give new key insights into the disease.
The study, which is a scientific milestone in this country, identifies four genes whose mutation causes this kind of leukemia.
In an act held last April during the XXII National Congress of the Spanish Society of Diabetes (SED) Antonio Zorzano, coordinator of the Molecular Medicine Programme at IRB Barcelona was awarded the IV “Alberto Sols Senior Investigator Award for Basic Research”. Presented by Bernat Soria, ex-president of the SED and ex-minister of Health, this award is in recognition of Zorzano’s career dedicated to the study of the causes of diabetes.
In 1991, Zorzano was one of the youngest Senior Professors in Spain in the...
The agreements drawn up by IRB Barcelona with various I+D programmes aim to strengthen technology transfer in order to benefit society.
Researchers at IRB Barcelona are to collaborate with international institutes to study the genetic code that determines cancer cell activity.
IRB Barcelona and the BSC show their commitment to computational biology by renewing the Joint IRB-BSC Programme, which also doubles in the number of researchers involved.
The programme aims to position itself as an international leader in computational biology.
The discovery provides intriguing new clues as to the cause of the disease and may lead to the development of novel therapeutic strategies.